Hepatitis B Vaccination in Responsive and Non-Responsive Patients with End-Stage Kidney Disease undergoing Hemodialysis
Iraqi Journal of Medical Sciences · 25.06.2026 · 24 (1) · 123-128
DOI: 10.22578/9hg3da13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iraqi Journal of Medical Sciences, online erschienen am 25.06.2026. Verfasst von Jawad A. Al-Joher und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Hepatitis B virus (HBV) vaccination is known as the best way to prevent the spread of the Hepatitis B virus in hemodialysis centers.
Objective
To study the effectiveness of the Euvax B vaccine in end-stage kidney disease (ESKD) Iraqi patients on hemodialysis already not responded to a series of doses of HBV vaccination before, using a different route of administration.
Methods
Forty-six ESKD patients on hemodialysis who did not respond to previous intramuscular HBV vaccination (defined as patients who had a series of intramuscular HBV vaccination doses and anti-hepatitis B virus surface antibody <10 IU/ml) were chosen. All 46 patients started on a new regimen of 4 doses of intramuscular recombinant HBV vaccination (Euvax B) 40 µg (double the regular dose for the non-dialysis population) at 0, 1, 2, and 6 months’ interval. The immune response has been studied after 2 and 4 doses. Patients who did not respond to all four doses had started intradermal vaccination of a 5 µg weekly dose for 8 weeks.
Results
Twenty-seven ESKD patients had responded to 2 doses of intramuscular doses (59%), while (70%) developed a response after completing 4 doses (P 0.001). Intramuscular injections are more effective with patients on hemodialysis for less than two years (P 0.02). Fourteen patients (who did not respond to Intramuscular doses) started on Intradermal administration of Euvax B, and nine patients (64%) responded to it.
Conclusion
Starting four doses of intramuscular HBV vaccination is effective and gives better outcomes if it is done in the early years of hemodialysis. Moreover, the intradermal route of administration of Euvax B is also effective for those who have not responded to intramuscular vaccination cycles.Keywords: Hepatitis B vaccination, ESKD, Euvax B, hemodialysis, non-responders, intradermal route
Zitieren
APA
Al-Joher, J. A., Talib, A. L., & Al-Delemi, M. A. (2026). Hepatitis B Vaccination in Responsive and Non-Responsive Patients with End-Stage Kidney Disease undergoing Hemodialysis. Iraqi Journal of Medical Sciences, 24(1), 123-128. https://doi.org/10.22578/9hg3da13
Vancouver
Al-Joher JA, Talib AL, Al-Delemi MA. Hepatitis B Vaccination in Responsive and Non-Responsive Patients with End-Stage Kidney Disease undergoing Hemodialysis. Iraqi Journal of Medical Sciences. 2026;24(1):123-128. doi:10.22578/9hg3da13
BibTeX
@article{AlJoher2026,
author = {Al-Joher, Jawad A. and Talib, Anmar L. and Al-Delemi, Mazin A.},
title = {Hepatitis B Vaccination in Responsive and Non-Responsive Patients with End-Stage Kidney Disease undergoing Hemodialysis},
journal = {Iraqi Journal of Medical Sciences},
year = {2026},
volume = {24},
number = {1},
pages = {123--128},
doi = {10.22578/9hg3da13}
}
EUVIMED